协和医学杂志

2020, v.11(05) 601-605

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

减瘤性肾切除术在转移性肾细胞癌治疗中的应用
Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma

郑国洋;张玉石;李汉忠;
ZHENG Guo-yang;ZHANG Yu-shi;LI Han-zhong;Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

摘要(Abstract):

减瘤性肾切除术在细胞因子治疗时代一度被推荐用于体能状态良好的转移性肾细胞癌的治疗。近年来,虽然靶向治疗广泛应用,减瘤性肾切除术仍是转移性肾细胞癌治疗的重要组成部分。随着CARMENA和SURTIME两项前瞻性研究的发表,减瘤性肾切除术在转移性肾细胞癌中的应用价值被重新审视。本文重点结合上述两项研究的结果以及相关思考,对减瘤性肾切除术在转移性肾细胞癌中的应用进展进行综述。
In the interferon era, cytoreductive nephrectomy was recommended for the treatment of patients with good performance status that were diagnosed with metastatic renal cell carcinoma. In recent years, in spite of the wide application of targeted therapy, cytoreductive nephrectomy is still an important part of the treatment of metastatic renal cell carcinoma. With the publication of two prospective studies, CARMENA and SURTIME, the role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma should be revalued. Based on the results and related considerations of above two studies, we reviewed recent progress in the application of cytoreductive nephrectomy in metastatic renal cell carcinoma.

关键词(KeyWords): 肾细胞癌;减瘤性肾切除术;靶向治疗;预后
renal cell carcinoma;cytoreductive nephrectomy;targeted therapy;prognosis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郑国洋;张玉石;李汉忠;
ZHENG Guo-yang;ZHANG Yu-shi;LI Han-zhong;Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享